

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2013

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
FORM 20-F  FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: December 9, 2013

By: /s/ "Kathi Niffenegger"  
Kathi Niffenegger  
Chief Financial Officer

**Exhibits:**

99.1 News Release dated December 9, 2013

## **Stellar Biotechnologies Announces Patents for Clostridium Difficile Immunotherapy Technology Issued in U.S. and China**

**PORT HUENEME, CA, (December 9, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH)**, the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced today the issuance of two additional patents, in the United States and in China, covering the Company's active immunotherapy technology for the treatment of *Clostridium difficile* infection ("C. diff").

*Clostridium difficile* is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.

The two patents, U.S. patent No. 8,597,663 and China patent No. 200880115518.2, describe certain novel cell surface polysaccharides and their chemical structures with broad claims covering antigen and vaccine compositions for the treatment, prevention and diagnosis of C. diff infection.

Stellar holds the exclusive, worldwide rights to develop, manufacture and sell human vaccines and other products derived from these patents, licensed from the University of Guelph. The license covers intellectual property related to the cell-wall polysaccharide of C. diff named PSII.

Stellar's technology combines PSII with Stellar KLH™ into an active immunotherapy approach with potential advantages over other technologies.

"Our PSII-KLH technology is dramatically different from other approaches," said Herbert Chow, Ph.D., Stellar's Chief Technology Officer. "We are harnessing the body's own immune system to disrupt the fundamental pathways of C. diff pathogenesis and transmission, unlike many methods which can only impact disease symptoms. These patents strengthen Stellar's intellectual property and further raise the barriers around our C. diff platform."

The novel combination of PSII-KLH is designed to activate innate and adaptive immune systems in the intestines that directly inhibit spore germination and reduce bacterial burden. In this way, Stellar's PSII-KLH vaccine is cell-directed to limit the extent and spread of disease transmission. Preliminary preclinical studies from Stellar's PSII-KLH active immunotherapy program demonstrated protection against C. diff in mice.

### **About Clostridium difficile**

*Clostridium difficile* is a major and growing cause of mortality and morbidity in hospitalized patients. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It is the leading cause of antibiotic-associated diarrhea and colitis. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported annually. Deaths related to C. diff increased 400% in recent years. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than \$7 billion annually.

### **About Stellar Biotechnologies, Inc.**

**Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF)** is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at <http://stellarbiotechnologies.com/contact/>

**Visit [www.StellarBiotech.com](http://www.StellarBiotech.com) and the KLH knowledge base [www.KLHSite.com](http://www.KLHSite.com).**

### **Company Contacts:**

Frank Oakes  
President and CEO  
Phone +1 (805) 488-2800  
[investorrelations@stellarbiotech.com](mailto:investorrelations@stellarbiotech.com)

Mark A. McPartland  
Vice President of Corporate Development and Communications  
Phone: +1 (805) 488-2800 ext. 103  
[markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com)

**Forward Looking Statements**

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.